Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $18.03 and last traded at $17.09, with a volume of 245,976 shares trading hands. The stock had previously closed at $14.94.

SNDX has been the subject of a number of analyst reports. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $24.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 17th. Zacks Investment Research raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Syndax Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $25.00.

The company’s 50-day moving average price is $12.72 and its 200 day moving average price is $13.16. The firm’s market capitalization is $263.53 million.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.07. On average, analysts forecast that Syndax Pharmaceuticals Inc. will post ($3.01) EPS for the current fiscal year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.